- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04705337
Levosimendan In Ambulatory Heart Failure Patients (LEIA-HF)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
It is a multicentre, randomized, double-blind, placebo-controlled study. 350 subjects will be included (in 12 or more medical centers) with severe HF, ejection fraction ≤35%, in New York Heart Association class III or IV. The other inclusion criteria concern: hospitalization for the HF decompensation in the last 3 months and a reduced six-minute walk test <350m or elevated NTproBNP ≥1000 pg / mL. To the European Society of Cardiology-guided, individually optimized medical therapy (OMT) the investigational product (IP) will be added. The subjects will be randomly assigned to one of the study group: 175 to the levosimendan arm and 175 to the placebo arm. The intervention studied in LEIA-HF trial is the administration of levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total). All study participants will also continue OMT. In the second phase of the study, after completing the levosimendan / placebo infusions, another 6 visits are planned, still double-blind, every 4 weeks, to assess the safety of treatment discontinuation (with optional return to the infusions by the Investigator when additional criteria for HF decompensation are met).
The efficacy of the treatment will be assessed after 52 weeks, 4 weeks after the last levosimendan / placebo administration.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Agnieszka Tycińska, Prof.
- Phone Number: +48 85 831 8656
- Email: agnieszka.tycinska@umb.edu.pl
Study Contact Backup
- Name: Andrzej Malkowski, PhD
- Phone Number: +48 85 686 5122
- Email: andrzej.malkowski@umb.edu.pl
Study Locations
-
-
-
Bialystok, Poland, 15-276
- Medical University of Bialystok Clinical Hospital
-
Principal Investigator:
- Agnieszka Tycińska, Prof. MD
-
Contact:
- Agnieszka Tycinska, Prof. MD
- Email: agnieszka.tycinska@umb.edu.pl
-
Bydgoszcz, Poland, 85-094
- Medical University Hospital No.1
-
Contact:
- Jacek Kubica, Prof. MD
-
Principal Investigator:
- Jacek Kubica, Prof. MD
-
Bydgoszcz, Poland, 85-168
- Medical University Hospital No.2
-
Contact:
- Grzegorz Grześk, Prof. MD
-
Principal Investigator:
- Grzegorz Grześk, Prof. MD
-
Gdańsk, Poland, 80-952
- Uniwersyteckie Centrum Kliniczne
-
Contact:
- Miłosz Jaguszewski, Prof. MD
-
Principal Investigator:
- Miłosz Jaguszewski, Prof. MD
-
Katowice, Poland, 40-635
- Górnośląskie Centrum Medyczne Śląskiego Uniwersytetu Medycznego
-
Contact:
- Wojciech Wojakowski, Prof. MD
-
Principal Investigator:
- Wojciech Wojakowski, Prof. MD
-
Kraków, Poland, 30-688
- Szpital Uniwersytecki w Krakowie
-
Contact:
- Barbara Zawiślak, PhD MD
-
Principal Investigator:
- Barbara Zawiślak, PhD MD
-
Kraków, Poland, 31-202
- John Paul II Hospital
-
Contact:
- Jadwiga Nessler, Prof. MD
-
Principal Investigator:
- Jadwiga Nessler, Prof. MD
-
Opole, Poland
- Medical University Hospital
-
Contact:
- Marek Gierlotka, Prof. MD
-
Principal Investigator:
- Marek Gierlotka, Prof. MD
-
Poznań, Poland, 61-848
- University Hospital of Lord's Transfiguration
-
Principal Investigator:
- Ewa Straburzyńska-Migaj, Prof. MD
-
Contact:
- Ewa Straburzyńska-Migaj, Prof. MD
-
Warszawa, Poland, 02-097
- Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego
-
Contact:
- Renata Główczyńska, ScD PhD MD
-
Principal Investigator:
- Renata Główczyńska, ScD PhD MD
-
Warszawa, Poland, 04-628
- Cardinal Stefan Wyszyński Institute of Cardiology
-
Contact:
- Janina Stępińska, Prof. MD
-
Principal Investigator:
- Janina Stępińska, Prof. MD
-
Wrocław, Poland, 50-556
- Uniwersytecki Szpital Kliniczny
-
Contact:
- Robert Zymliński, ScD PhD MD
-
Principal Investigator:
- Robert Zymliński, ScD PhD MD
-
Zabrze, Poland, 41-800
- Slaskie Centrum Chorob Serca
-
Contact:
- Mariusz Gąsior, Prof. MD
-
Principal Investigator:
- Mariusz Gąsior, Prof. MD
-
Łódź, Poland, 91-347
- Provincial Specialist Hospital named after Dr. Wł. Biegański
-
Contact:
- Jarosław Kasprzak, Prof. MD
-
Principal Investigator:
- Jarosław Kasprzak, Prof. MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed consent obtained before any trial activities
- Male or female, age ≥ 18 years at the time of signing informed consent
- Left ventricle ejection fraction ≤ 35%
- Hospitalization due to worsening of HF within the last 3 months
- New York Heart Association functional class III or outpatient IV
- Individually optimized pharmacotherapy, based on the current European Society of Cardiology recommendations, stable for at least 1 month prior to randomization, according to the knowledge and experience of the qualifying clinician
- Distance covered in six-minute walk test <350m OR NTproBNP concentration ≥ 1000 pg/mL
- In the opinion of the Investigator, the patient does not currently require hospitalization
- Patient protected with an implantable device capable of terminating life-threatening arrhythmias and conduction disturbances (ICD or cardiac resynchronisation therapy-D/P), if indicated and the patient consents to implantation.
Exclusion Criteria:
- Known or suspected hypersensitivity to trial products or related products,
- Restrictive or hypertrophic cardiomyopathy, uncorrected severe valvular disease, potentially reversible cause of HF
- Hypotension with symptoms of tissue hypoperfusion
- Uncontrolled hypertension
- Planned revascularization or other surgical treatment of HF within the next year
- Advanced chronic kidney disease
- Features of liver damage
- Severe chronic lung disease with features of respiratory distress or severe abnormal spirometry or home oxygen treatment
- Accompanying chronic diseases with poor prognosis
- Paroxysmal supraventricular tachycardia, paroxysmal ventricular tachycardia, torsade de pointes, advanced atrioventricular blocks within one month prior to screening
- Receipt of any investigational product within 30 days before screening visit
- Any disorder, which in the investigator's opinion may jeopardise subject's safety or compliance with the study protocol and procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
administration of placebo
|
administration of glucose as a continuous iv.
infusion, every 4 weeks for 48 weeks (12 infusions in total)
|
Experimental: Levosimendan
administration of levosimendan
|
administration of levosimendan as a continuous iv.
infusion, every 4 weeks for 48 weeks (12 infusions in total)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the number of unplanned hospitalization
Time Frame: 12 months of follow-up period
|
unplanned hospitalization due to heart failure decompensation
|
12 months of follow-up period
|
the number of deaths
Time Frame: 12 months of follow-up period
|
death for any cause
|
12 months of follow-up period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
total mortality calculations
Time Frame: 0-12, 12-18 and 0-18 months
|
total mortality for any cause
|
0-12, 12-18 and 0-18 months
|
cardiovascular mortality calculations
Time Frame: 0-12, 12-18 and 0-18 months
|
mortality due to cardiovascular reasons
|
0-12, 12-18 and 0-18 months
|
the number of planned hospitalization
Time Frame: 0-12, 12-18 and 0-18 months
|
planned hospitalization due to heart failure decompensation
|
0-12, 12-18 and 0-18 months
|
the number of implantations of mechanical circulatory support
Time Frame: 0-12, 12-18 and 0-18 months
|
implantation of mechanical circulatory support
|
0-12, 12-18 and 0-18 months
|
the number of heart transplantations
Time Frame: 0-12, 12-18 and 0-18 months
|
heart transplantation
|
0-12, 12-18 and 0-18 months
|
quality of life measurements
Time Frame: 0-12, 12-18 and 0-18 months
|
The Kansas City Cardiomyopathy Questionnaire quality of life questionnaire- an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains.
For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established.
Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
|
0-12, 12-18 and 0-18 months
|
the six-minute walk test
Time Frame: 0-12, 12-18 and 0-18 months
|
measures the distance an individual is able to walk over a total of six minutes
|
0-12, 12-18 and 0-18 months
|
NTproBNP measurements
Time Frame: 0-12, 12-18 and 0-18 months
|
measurements of NTproBNP concentrations
|
0-12, 12-18 and 0-18 months
|
estimated glomerular filtration rate measurements
Time Frame: 0-12, 12-18 and 0-18 months
|
measurements of estimated glomerular filtration rate
|
0-12, 12-18 and 0-18 months
|
echocardiographic parameters
Time Frame: 0-12, 12-18 and 0-18 months
|
the change in echocardiographic parameters assessed in transthoracic echocardiographic examination (TTE)
|
0-12, 12-18 and 0-18 months
|
patients who returned to levosimendan / placebo infusions
Time Frame: from the 12th to the 18th months of the study
|
calculations of the percentage of patients who returned to levosimendan / placebo infusions
|
from the 12th to the 18th months of the study
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Agnieszka Tycińska, Prof. MD, Medical University of Bialystok
- Principal Investigator: Marek Gierlotka, Prof. MD, University of Opole
- Principal Investigator: Jarosław Kasprzak, Prof. MD, Medical University of Łódź
- Principal Investigator: Jacek Kubica, Prof. MD, Nicolaus Copernicus University in Toruń
- Principal Investigator: Grzegorz Grześk, Prof. MD, Nicolaus Copernicus University in Toruń
- Principal Investigator: Jadwiga Nessler, Prof. MD, John Paul II Hospital, Krakow
- Principal Investigator: Janina Stępińska, Prof. MD, Cardinal Stefan Wyszyński Institute of Cardiology
- Principal Investigator: Ewa Straburzyńska-Migaj, Prof. MD, Poznan University of Medical Sciences
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019/ABM/01/00017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure, Systolic
-
Zensun Sci. & Tech. Co., Ltd.Active, not recruitingChronic Systolic Heart FailureChina
-
Zensun Sci. & Tech. Co., Ltd.TerminatedChronic Systolic Heart FailureChina
-
Central Hospital, Nancy, FranceUnknown
-
Hospital Moinhos de VentoTakedaUnknownHeart Failure, Systolic | Systolic Heart Failure | Cardiac FailureBrazil
-
Jiangsu HengRui Medicine Co., Ltd.UnknownChronic Systolic Heart FailureChina
-
Merck KGaA, Darmstadt, GermanyMerck Ltd.Completed
-
University of NebraskaEli Lilly and Company; Daiichi Sankyo, Inc.Completed
-
Abbott Medical DevicesCompletedSystolic Heart FailureAustralia, Hong Kong, Japan
-
University of CincinnatiCompletedSystolic Heart FailureUnited States
-
Novartis PharmaceuticalsCompletedHeart FailureRussian Federation, Germany, Poland
Clinical Trials on Levosimendan
-
Central Hospital, Nancy, FranceRecruitingCardiac Surgery | Heart Failure With Reduced Ejection Fraction | LevosimendanFrance
-
National Taiwan University HospitalUnknown
-
Aretaieion University HospitalCompletedHypertension, Pulmonary | Pulmonary Vascular Resistance Abnormality | Cardiac FailureGreece
-
Assistance Publique - Hôpitaux de ParisRecruitingCardiogenic Shock | Extracorporeal Membrane Oxygenation ComplicationFrance
-
Aretaieion University HospitalCompletedCardiac Surgery | Cardiac Disease | Cardiac Failure | Inotropes | Ejection FractionGreece
-
Orion Corporation, Orion PharmaCompletedAmyotrophic Lateral SclerosisCanada, United States, Australia, Austria, United Kingdom, Germany, Finland, Spain, France, Italy, Sweden, Netherlands, Belgium, Ireland
-
Orion Corporation, Orion PharmaCompletedAmyotrophic Lateral SclerosisIreland, Netherlands, United Kingdom, Germany
-
Cancer Institute and Hospital, Chinese Academy...RecruitingHead and Neck Squamous Cell CarcinomaChina
-
Tenax Therapeutics, Inc.CompletedHeart Failure With Normal Ejection Fraction | Heart Failure, Right Sided | Hypertension Pulmonary SecondaryUnited States
-
Dr. Gerhard PölzlOrion Corporation, Orion PharmaUnknown